{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:29:37Z","timestamp":1783603777076,"version":"3.55.0"},"reference-count":81,"publisher":"Portland Press Ltd.","issue":"4","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alport syndrome is a rare genetic disease that results in disordered basement membrane type IV collagen resulting in occular and auditory defects as well of progressive kidney disease. Although no \u2018cure\u2019 currently exists, therapeutic blockade of the renin\u2013angiotensin\u2013aldosterone system can slow the progression to end-stage kidney disease (ESKD). Clinical trials for treatments in preventing chronic kidney disease have largely been negative over the last two decades until recent trials have shown positive cardiovascular and renal outcomes of sodium\u2013glucose co-transporter-2 (SGLT2) inhibitors in patients with diabetes mellitus. Although marketed as medications for Type 2 diabetes, SGLT2 inhibitors have been found to have additional properties that are nephroprotective which makes them a potential candidate for treatment for those with other forms of progressive kidney disease. This review discusses the evidence for the use of SGLT2 inhibitors as a potential treatment in Alport syndrome that may slow the progression of chronic kidney disease and prevent patients reaching ESKD.<\/jats:p>","DOI":"10.1042\/cs20191276","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T09:28:54Z","timestamp":1581931734000},"page":"379-388","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["SGLT2 inhibitors \u2013 a potential treatment for Alport syndrome"],"prefix":"10.1042","volume":"134","author":[{"given":"Holly","family":"Mabillard","sequence":"first","affiliation":[{"name":"Renal Services, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1881-3782","authenticated-orcid":false,"given":"John\u00a0A.","family":"Sayer","sequence":"additional","affiliation":[{"name":"Renal Services, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, U.K."},{"name":"Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Central Parkway, Newcastle upon Tyne NE1 3BZ, U.K."},{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle University, NE4 5PL, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"2021113011101917200_B1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Percovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2021113011101917200_B5","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s13300-019-0657-8","article-title":"SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c - Translating Evidence into Practice","volume":"10","author":"Ali","year":"2019","journal-title":"Diabetes Ther."},{"key":"2021113011101917200_B6","article-title":"Alport syndrome","author":"Meroni","year":"2007","journal-title":"Orphanet"},{"key":"2021113011101917200_B7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","article-title":"Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport syndrome Classification Working Group","volume":"93","author":"Kashtan","year":"2018","journal-title":"Kidney Int."},{"key":"2021113011101917200_B8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00467-018-3985-4","article-title":"Expert consensus guidelines for the genetic diagnosis of Alport syndrome","volume":"34","author":"Savige","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"2021113011101917200_B9","doi-asserted-by":"publisher","first-page":"e0161802","DOI":"10.1371\/journal.pone.0161802","article-title":"X-linked and autosomal recessive Alport syndrome: pathogenic variant features and further genotype-phenotype correlations","volume":"11","author":"Savige","year":"2016","journal-title":"PLoS One"},{"key":"2021113011101917200_B10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/CJN.00580116","article-title":"Alport syndrome in women and girls","volume":"11","author":"Savige","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2021113011101917200_B11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/ijms20030519","article-title":"Kidney injury by variants in theCOL4A5 gene aggravated by polymorphisms in slit diaphragm genes causes focal segmental glomerulosclerosis","volume":"20","author":"Frese","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"2021113011101917200_B12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12882-018-0906-5","article-title":"COL4A5 and LAMA5 variants co-inherited in familial hematuria: digenic inheritance or genetic modifier effect?","volume":"19","author":"Voskarides","year":"2018","journal-title":"BMC Nephrol."},{"key":"2021113011101917200_B13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1681\/ASN.2008090984","article-title":"The Renal Lesions of Alport syndrome","volume":"20","author":"Heidet","year":"2009","journal-title":"JASN"},{"key":"2021113011101917200_B14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/ki.2014.326","article-title":"Pathology vs. molecular genetics: (re) defining the spectrum of Alport syndrome","volume":"86","author":"Miner","year":"2014","journal-title":"Kidney Int."},{"key":"2021113011101917200_B15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0021-9975(97)80016-3","article-title":"Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor","volume":"117","author":"Grodecki","year":"1997","journal-title":"J. Comp. Pathol."},{"key":"2021113011101917200_B16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/ki.2011.452","article-title":"Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations","volume":"81","author":"Temme","year":"2012","journal-title":"Kidney Int."},{"key":"2021113011101917200_B17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Pre-emptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int."},{"key":"2021113011101917200_B18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int."},{"key":"2021113011101917200_B19","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4158\/EP.14.6.782","article-title":"Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus","volume":"14","author":"Abdul-Ghani","year":"2008","journal-title":"Endocr. Pract."},{"key":"2021113011101917200_B20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"2021113011101917200_B21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycaemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011101917200_B22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"2021113011101917200_B23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt","year":"2014","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"2021113011101917200_B24","doi-asserted-by":"publisher","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"2021113011101917200_B25","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"2021113011101917200_B26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1152\/physrev.00042.2012","article-title":"Renal autoregulation in health and disease","volume":"95","author":"Carlstr\u00f6m","year":"2015","journal-title":"Physiol. Rev."},{"key":"2021113011101917200_B27","first-page":"182","article-title":"Activation of renin in the single juxtaglomerular apparatus by sodium chloride in the tubular fluid at the macula densa","volume":"31","author":"Thurau","year":"1972","journal-title":"Circ. Res."},{"key":"2021113011101917200_B28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"2021113011101917200_B29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"2021113011101917200_B30","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1681\/ASN.2009070759","article-title":"Macula Densa Sensing and Signaling Mechanisms of Renin Release","volume":"21","author":"Peti-Peterdi","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011101917200_B31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/ki.1997.111","article-title":"A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function","volume":"51","author":"Apperloo","year":"1997","journal-title":"Kidney Int."},{"key":"2021113011101917200_B32","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and type IV collagen","volume":"348","author":"Hudson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B33","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1681\/ASN.2008101086","article-title":"Cellular origins of type IV collagen networks in developing glomeruli","volume":"20","author":"Abrahamson","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011101917200_B34","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1097\/01.ASN.0000141462.00630.76","article-title":"The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family","volume":"15","author":"Hudson","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011101917200_B35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrneph.2012.259","article-title":"Alport syndrome - insights from basic science and clinical research","volume":"9","author":"Kruegel","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"2021113011101917200_B36","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/ndt\/17.7.1218","article-title":"Meta-analysis of genotype-phenotype correlation in x-linked Alport syndrome: impact on clinical counselling","volume":"17","author":"Gross","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021113011101917200_B37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/jemt.20564","article-title":"Mammalian collagen IV","volume":"71","author":"Khoshnoodi","year":"2008","journal-title":"Microsc. Res. Tech."},{"key":"2021113011101917200_B38","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/ki.2009.324","article-title":"Biochemical strain causes maladaptive gene regulation, contributing to Alport glomerular disease","volume":"76","author":"Meehan","year":"2009","journal-title":"Kidney Int."},{"key":"2021113011101917200_B39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1523-1755.2004.00712.x","article-title":"DDR1 deficient mice show localized subepithelial GBM thickening with focal loss of slit-diaphragms and proteinuria","volume":"66","author":"Gross","year":"2004","journal-title":"Kidney Int."},{"key":"2021113011101917200_B40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1755-1536-3-19","article-title":"Integrin alpha2-deficinet mice provide insights into specific functions of collagen receptors in the kidney","volume":"3","author":"Girgert","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2021113011101917200_B41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1128\/MCB.24.2.550-560.2004","article-title":"Early glomerular filtration defect and severe renal disease in podocin-deficient mice","volume":"24","author":"Roselli","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"2021113011101917200_B42","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/sj.ki.5002707","article-title":"Nephrin is involved in podocyte maturation but not survival during glomerular development","volume":"73","author":"Done","year":"2008","journal-title":"Kidney Int."},{"key":"2021113011101917200_B43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive Ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int."},{"key":"2021113011101917200_B44","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2337\/dbi18-0006","article-title":"Sodium-glucose cotransporter 2 inhibitor: a case study in translational research","volume":"68","author":"Beitelshees","year":"2019","journal-title":"Diabetes"},{"key":"2021113011101917200_B45","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B46","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B47","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease","volume":"355","author":"Singh","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B48","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B49","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B50","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B51","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design","volume":"24","author":"Parving","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021113011101917200_B52","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease","volume":"369","author":"De Zeeuw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B54","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B55","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.ajkd.2010.09.025","article-title":"Sevelamer Prescriptions After Reporting of the Dialysis Clinical Outcomes Revisited (DCOR) Trial Findings: An Analysis of 5,495 Patients Receiving Maintenance Dialysis in Ontario, Canada","volume":"57","author":"Weir","year":"2001","journal-title":"AJKD"},{"key":"2021113011101917200_B56","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2021113011101917200_B57","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"2021113011101917200_B58","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.jacc.2005.10.064","article-title":"Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure","volume":"47","author":"Zoungas","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011101917200_B59","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1001\/jama.298.10.1163","article-title":"Veterans Affairs Site Investigators: Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial","volume":"298","author":"Jamison","year":"2007","journal-title":"JAMA"},{"key":"2021113011101917200_B60","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"2021113011101917200_B61","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1080\/03007995.2016.1174841","article-title":"The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus","volume":"32","author":"Alba","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"2021113011101917200_B62","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of Hypoparathyroidism: Present and Future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113011101917200_B63","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/dom.13480","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study","volume":"21","author":"Schmedt","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"2021113011101917200_B64","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"2021113011101917200_B65","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7326\/M18-0567","article-title":"Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study","volume":"170","author":"Fralick","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"2021113011101917200_B66","doi-asserted-by":"crossref","first-page":"e007165","DOI":"10.1161\/JAHA.117.007165","article-title":"Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patinets With Type 2 Diabetes Mellitus: A Systematic Review and meta-Analysis With Trial Sequential Analysis","volume":"20","author":"Zhang","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"2021113011101917200_B67","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2337\/dc19-0849","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and the risk of Fractures Among Patients With Type 2 Diabetes","volume":"42","author":"Abrahami","year":"2019","journal-title":"Diabetes Care"},{"key":"2021113011101917200_B68","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/diaclin.28.1.5","article-title":"Apple Trees to Sodium Glucose Co-Transporter Inhibitors: A Review of SGLT2 Inhibition","volume":"28","author":"White","year":"2010","journal-title":"Clinical Diabetes"},{"key":"2021113011101917200_B69","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1681\/ASN.2017101062","article-title":"Should We Increase GFR with Bardoxolone in Alport syndrome","volume":"29","author":"Baigent","year":"2018","journal-title":"JASN"},{"key":"2021113011101917200_B70","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011101917200_B71","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1681\/ASN.2009070784","article-title":"Genotype-Phenotype Correlation in X-Linked Alport syndrome","volume":"21","author":"Bekheirnia","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011101917200_B72","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s10157-018-1629-4","article-title":"A review of clinical characteristics and genetic backgrounds in Alport syndrome","volume":"23","author":"Nozu","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"2021113011101917200_B73","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011101917200_B74","doi-asserted-by":"publisher","first-page":"12696","DOI":"10.1038\/s41598-019-48990-9","article-title":"Determination of the pathogenicity of known COL4A5 intronic variants by in vitro splicing assay","volume":"9","author":"Horinouchi","year":"2019","journal-title":"Sci. Rep."},{"key":"2021113011101917200_B75","article-title":"Exon Skipping Therapy for COL4A5 Gene Truncating Variant Rescued Progression of Kidney Failure in X-Linked Alport syndrome [abstract]","volume-title":"American Society of Nephrology","author":"Tomohiko","year":"2019"},{"key":"2021113011101917200_B76","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.2215\/CJN.09100817","article-title":"COL4A3 Gene Variants and Diabetic Kidney Disease in MODY","volume":"13","author":"Wang","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol"},{"key":"2021113011101917200_B77","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/ndt\/gfv325","article-title":"Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis","volume":"31","author":"Gast","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021113011101917200_B78","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00467-013-2533-5","article-title":"Diagnosis of Alport syndrome - search for proteomic biomarkers in body fluids","volume":"28","author":"Pohl","year":"2013","journal-title":"Paediatr. Nephrol."},{"key":"2021113011101917200_B79","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1097\/01.ASN.0000090034.71205.74","article-title":"X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \u201cEuropean Community Alport syndrome Concerted Action\u201d study","volume":"14","author":"Jais","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113011101917200_B80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.kint.2019.09.023","article-title":"Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes","volume":"97","author":"Bjornstad","year":"2020","journal-title":"Kidney Int."},{"key":"2021113011101917200_B81","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin treated patients with type 2 diabetes in the randomised, double blind RED trial","volume":"97","author":"Van Bommel","year":"2020","journal-title":"Kidney Int."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/4\/379\/867917\/cs-2019-1276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/4\/379\/867917\/cs-2019-1276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T18:59:29Z","timestamp":1665860369000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/134\/4\/379\/222128\/SGLT2-inhibitors-a-potential-treatment-for-Alport"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2,28]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20191276","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2020,2]]}}}